<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82AC974D-4565-4BCE-A841-D5259A9B6D0D"><gtr:id>82AC974D-4565-4BCE-A841-D5259A9B6D0D</gtr:id><gtr:name>Sealife Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15D3C1D3-84F0-48E8-8480-71DDFF4D82C5"><gtr:id>15D3C1D3-84F0-48E8-8480-71DDFF4D82C5</gtr:id><gtr:name>Children's Hospital Oakland Research Institute (CHORI)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82AC974D-4565-4BCE-A841-D5259A9B6D0D"><gtr:id>82AC974D-4565-4BCE-A841-D5259A9B6D0D</gtr:id><gtr:name>Sealife Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15D3C1D3-84F0-48E8-8480-71DDFF4D82C5"><gtr:id>15D3C1D3-84F0-48E8-8480-71DDFF4D82C5</gtr:id><gtr:name>Children's Hospital Oakland Research Institute (CHORI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0549AE03-83A7-456B-B9EC-6790271B75F3"><gtr:id>0549AE03-83A7-456B-B9EC-6790271B75F3</gtr:id><gtr:firstName>Chas</gtr:firstName><gtr:surname>Bountra</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13073"><gtr:id>43345946-CAF6-44AC-9BA4-355D8AF883BC</gtr:id><gtr:title>UoOxford Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13073</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>650000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Children's Hospital Oakland Research Institute (CHORI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>A novel vaccine for broad protection against meningococcal disease: selection of the optimal product composition for a phase I clinical trial</gtr:description><gtr:id>2D6FC884-6419-4803-9BBE-996F1699C704</gtr:id><gtr:impact>Potential for patents and publications</gtr:impact><gtr:outcomeId>56df565c058555.67009188-1</gtr:outcomeId><gtr:partnerContribution>Our partner has provided sequences for proteins to be included in a vaccine candidate</gtr:partnerContribution><gtr:piContribution>We established a fruitful and successful collaboration with P. Beernink at CHORI, Oakland, USA. We have provided expertise in vaccine development</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sealife Pharma</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Antibacterial bioassays</gtr:description><gtr:id>905C186B-CEE7-4E17-A1FA-D6128C247BD7</gtr:id><gtr:impact>Data not finalised yet</gtr:impact><gtr:outcomeId>56d46e6af3ba76.16484099-1</gtr:outcomeId><gtr:partnerContribution>Supply of antibacterial bioassays</gtr:partnerContribution><gtr:piContribution>Supply of new chemical entities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medicine, Dentistry &amp; Nursing</gtr:department><gtr:description>Preclinical evaluation of a vaccine for Psoriasis</gtr:description><gtr:id>A31DDC43-34C2-444A-AF51-619A04D8D395</gtr:id><gtr:impact>Publication of a review article
Co-application for further funding
Formed a new company - HealVax GmbH, currently seeking investment to fund GMP manufacture and phase I clinical trial.</gtr:impact><gtr:outcomeId>56d99703db2486.19892480-1</gtr:outcomeId><gtr:partnerContribution>Performed experiments - Preclinical studies and analysis of outcomes</gtr:partnerContribution><gtr:piContribution>Discussion and design of experiments 
Provision of vaccine and related materials for preclinical studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Industrial collaboration</gtr:description><gtr:id>5CF9A0A8-B268-4C55-9062-91F676F725DE</gtr:id><gtr:impact>No finalised outcomes yet</gtr:impact><gtr:outcomeId>56d46e079f0022.13021706-1</gtr:outcomeId><gtr:partnerContribution>Supply of bioassay and expertise</gtr:partnerContribution><gtr:piContribution>Supply of new chemical entities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Auckland</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Faculty of Medical and Health Sciences</gtr:department><gtr:description>Clinical Interpretation of SWAS</gtr:description><gtr:id>9AA76453-86AA-41F9-9F0D-418B839BF5E3</gtr:id><gtr:impact>We are preparing a paper for submission to a high-impact anaesthetic journal in the next month. The collaboration is multi-disciplinary covering the fields of neuroscience and clinical anaesthesia.</gtr:impact><gtr:outcomeId>56de3cb94e2417.25712815-1</gtr:outcomeId><gtr:partnerContribution>Professor Jamie Sleigh, a world leader in electroencephalography under anaesthesia research, provided clinical EEG datasets acquired under surgical anaesthesia that allowed us to test and refine the SWAS Bayesian modelling in the clinical environment.</gtr:partnerContribution><gtr:piContribution>We identified slow wave activity saturation (SWAS), generated the Bayesian model to determine whether an individual had achieved SWAS and applied this to our experimental data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Research Meeting, MRC HQ London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CD633A44-8388-4D19-AE80-DFCCEA02B98F</gtr:id><gtr:impact>Meeting of potential investigators (psychiatrists and neurologists) to set up a network across England to seek out people with antibody-mediated psychosis and then offer them the change to be in a randomised controlled trial, to test the pathogenicity of these antibodies, using IVIG and rituximab.</gtr:impact><gtr:outcomeId>56c5b05d5cdad3.15109604</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Rethink Mental Illness charity, Harrogate May 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D17EC1FD-F79B-4A10-A127-3F1F482B21CE</gtr:id><gtr:impact>Presentation to Rethink Mental Illness charity in Harrogate, May 2015. Title: Brains on Fire.</gtr:impact><gtr:outcomeId>56d43baa5b62d9.28572556</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium speaker at British Neuroscience Association Festival of Neuroscience 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AD77F389-39E6-4D7A-83D8-C95561091776</gtr:id><gtr:impact>Presentation detailing how brain activity in altered physiological states such as anaesthesia and pain could be quantified using functional imaging to an audience of ~100 UK neuroscientists.</gtr:impact><gtr:outcomeId>56df96e5d61474.83306011</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at British Journal of Anaesthesia Research Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57EFB209-5A21-4BC5-B957-4BCE424A140A</gtr:id><gtr:impact>Presented outcome of work completed on award to anaesthetists - potential end users. It was observed to be a big step towards individualised depth of anaesthesia monitoring.</gtr:impact><gtr:outcomeId>58c7d77aa13b48.43162603</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at the 6th European Conference on Schizophrenia Research (ECSR)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F855D250-1A6C-4FB7-B821-D127A8E0E302</gtr:id><gtr:impact>Symposium presentation entitled: &amp;quot;The diagnosis and management of autoimmune encephalitis in psychiatric settings&amp;quot; at the 6th European Conference on Schizophrenia Research (ECSR), 24/11/2016</gtr:impact><gtr:outcomeId>58a464ba54f801.46642512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.cpo-media.net/DGPPN/2016/Programm/HTML/files/assets/common/downloads/publication.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Attendee and Speaker at ACCESS conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>61546F1E-A470-4842-BE87-E00CED55C8D0</gtr:id><gtr:impact>Recent data was presented to the ACCESS group - Anesthesiologists concerned with Cognition, Emergence, Sedation and Sleep - to update the audience on progress made towards understanding brain activity alterations on induction and emergence from general anaesthesia.</gtr:impact><gtr:outcomeId>56df8d7a4b0947.08322910</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3282E92A-080D-429A-8469-F33762CFC98B</gtr:id><gtr:impact>BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind.</gtr:impact><gtr:outcomeId>58a46a9bcb7773.96008194</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b07pj2pw</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alports Syndrome International Workshop (2015)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB1FC86A-708E-4A35-8408-D968422561CB</gtr:id><gtr:impact>Presentation to ~150 people attending international workshop on Alports syndrome. Individuals included patients, carers and scientific researchers. Introduced new therapeutic concepts. Wide ranging discussions followed.</gtr:impact><gtr:outcomeId>56c34b27b3c3d8.52911491</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations to psychiatric teams: January - Reading, February - Oxford, March - Buckinghamshire, May - Swindon, June - Chippenham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9FE9B0AE-21F4-4B36-AA21-2FB2B5717574</gtr:id><gtr:impact>Antibodies and psychosis - what psychiatrists need to know - presentations to psychiatric teams: Reading Jan 2015, Oxford Feb 2015, Buckinghamshire March 2015, Swindon May 2015, Chippenham June 2015</gtr:impact><gtr:outcomeId>56d43d3d516812.43157970</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Urgent Care Research Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3EE873E1-9470-4A8E-A8ED-14F399C37A73</gtr:id><gtr:impact>Targeted clinicians and researchers involved with NIHR Clinical Research Network Thames Valley and South Midlands</gtr:impact><gtr:outcomeId>58c7d8968a1e64.32557353</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Antruk</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B00CB54B-61EC-47B4-935C-4F38C8EFCCCB</gtr:id><gtr:impact>Establishement of ANTRUK</gtr:impact><gtr:outcomeId>56d46edc24b9f5.24517356</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.antibioticresearch.org.uk/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness public engagement event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE8A9AA1-126C-44D5-A868-29C853E10F35</gtr:id><gtr:impact>A public engagement activities event at the History of Science Museum in Oxford. This was attended by members of the general public. It was free entry and many attendees were international visitors. The public were invited to look through microscopes at histological slides of human brain tissue (all confirmed ethical approval) and discuss what they could see. This was particularly appealing to a group of boys (age 7-11) visiting from Poland. But it also engaged some carers and relatives of people with dementia. In addition, a computer game had been developed by Dr Chance to engage youngsters with the neuroscience of Alzheimer's disease. Playing a fictional character 'shrunk to the size of a cell' the 1 or 2 players descended through the 'cortex' combating mutant tau and avoiding amyloid plaques in order to find stem cells in the sub-ventricular zone and transport them to the hippocampus to rewire into memory circuits. This was played enthusiastically by groups of girls and boys. One little boy's father requested access to the game for his son who returned later in the day in order to complete it. (Unfortunately it was not possible to distrbute the game).</gtr:impact><gtr:outcomeId>58c82e1848a8c1.15064609</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited seminar at Oxford Centre for Human Brain Activity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D7191703-1B45-41C8-8572-679734E0614B</gtr:id><gtr:impact>Discussion of the current understanding of the effects of anaesthesia on brain function.</gtr:impact><gtr:outcomeId>56df8f7c8db3c2.54699643</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford University Hospitals NHS Foundation Trust Audit Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E2260215-6F0A-4C92-B0EE-B1D3FC7DBC2D</gtr:id><gtr:impact>I gave the University lecture at the Nuffield Department of Anaesthesia Audit on &amp;quot;Anaesthesia and Brain Function&amp;quot; to the practising anaesthetists within the local NHS Trust. It was described as the &amp;quot;most clinically relevant lecture in years&amp;quot; and &amp;quot;potentially ground breaking&amp;quot; research.</gtr:impact><gtr:outcomeId>56df963d3e2ec1.45166541</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation: The prevalence of antibodies against neuronal cell surface targets in acute first episode psychosis, 15th International Congress on Schizophrenia Research' in Colorado Springs, Colorado, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8A64FB3B-AC19-4FB5-A028-B85667962142</gtr:id><gtr:impact>This was a plenary session attended by academics and clinicians. Members of the audience remarked they were more convinced by the research presented in this session than had been heard previously.</gtr:impact><gtr:outcomeId>56c49f70113240.10265266</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>25F9FA3D-73D6-4FC8-ABAC-B929FFF67CF4</gtr:id><gtr:impact>Lecture initiated questions on working in STEM subjects

Considerable interest from talented students to pursue career in research, particularly Oxford</gtr:impact><gtr:outcomeId>546352292773d8.70628286</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote address, Encephalitis Society Professional Seminar 2015, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>80FF5CDF-B2D9-4D7D-A524-CE41F4DFB2EE</gtr:id><gtr:impact>Keynote address: What do psychiatrists have to offer in the management of Augoimmune Encephalitis</gtr:impact><gtr:outcomeId>56c5ac393bbc25.09067632</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.encephalitis.info/files/2714/4596/2037/Prof_seminar_2015_WEB.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC World Service - World Have Your Say - 2017/03/03</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>10A57AE2-76D5-4CD4-83CD-217F967D9505</gtr:id><gtr:impact>BBC World Service Discussion Programme regarding gene therapy in general, specially the use of lentiviral vectors and the correction of sickle cell anaemia.</gtr:impact><gtr:outcomeId>58befde0811304.40667132</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/p04tv5n9</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dessimination: Neurosciences Grand Round, John Radcliffe Hospital, Oxford.  April 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>596D9A06-92F4-49EE-9E9A-3EBC594272CB</gtr:id><gtr:impact>Psychiatric channelopathies - Neurosciences Grand Round, John Radcliffe Hospital April 2015</gtr:impact><gtr:outcomeId>56d456ed928c05.22759720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Talk (Bradfield College 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D6C1636A-18CD-403D-8BBD-462F1F5D0BB2</gtr:id><gtr:impact>Science discussion evenning event at Bradfield College. Wide ranging audience from school children to CF care givers and relatives. Talk stimulated extensive discussion and questions.</gtr:impact><gtr:outcomeId>56c349aebc9bb2.85585112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Sciences Innovation Life Sciences Event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CE861DB9-F829-4403-AC64-4E99AE3892A1</gtr:id><gtr:impact>Presentation of MRC CiC funded project on Slow wave activity saturation (SWAS) as a marker of depth of anaesthesia at local event for previous awardees and future applicants.</gtr:impact><gtr:outcomeId>56df91ff2bf5d2.60359979</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies at Association of British Neurologists Annual Meeting, Harrogate</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>50CD4866-5F5E-4443-91FB-4CD9A5BA619C</gtr:id><gtr:impact>Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies</gtr:impact><gtr:outcomeId>56c4a3c1b63417.18279151</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.theabn.org/media/docs/Meetings/2015%20ABN%20Harrogate%20draft%20programme_28.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2187000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Pathway Funding Scheme</gtr:description><gtr:end>2021-04-02</gtr:end><gtr:fundingOrg>MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS)</gtr:fundingOrg><gtr:id>60DEB97C-0D70-4AB1-9D59-E4FEA7A05069</gtr:id><gtr:outcomeId>58c3e9152b3967.52961371</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Trust</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>F5445F3D-1562-4C0B-89AD-EEDCC9DFF91E</gtr:id><gtr:outcomeId>5460ba46cec6c1.87391155</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250683</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centres of Excellence in Neurodegeneration</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>1509HM013/NF2</gtr:fundingRef><gtr:id>91EC83FE-AD10-4350-ACF1-B4B196D23EB0</gtr:id><gtr:outcomeId>56dd40c3307197.77781093</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2262504</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2021-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>104633/Z/14/Z</gtr:fundingRef><gtr:id>754F6E17-7EEC-4306-BDC0-C51B41AC4EA0</gtr:id><gtr:outcomeId>56d85aee311268.67460481</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2711780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N019067/1</gtr:fundingRef><gtr:id>6E6B31C3-E4DA-4FEA-8D4C-CEB8449AAF10</gtr:id><gtr:outcomeId>56d451b0402787.53337426</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>vaccines for global epidemics - preclinical (Q fever)</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:id>1A94E10D-2B43-48B5-A13F-CDC6FD520892</gtr:id><gtr:outcomeId>58c41d4beb85e5.28377356</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150135</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Wellcome Trust ISSF</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DCCCD872-BB42-4BCD-AB93-7665EDC75CA3</gtr:id><gtr:outcomeId>5460be7e2b8a02.64268244</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Discovery Award - Identification and characterisation of cellular targets for genome editing of foetal haematopoietic stem/progenitor cells</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>747587A5-1D1F-4DF1-85F5-6F1179219249</gtr:id><gtr:outcomeId>58b6a4a9005112.71293115</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17849</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 3</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00553010-22BE-4439-AE54-48E29B225714</gtr:id><gtr:outcomeId>58c7d3d8df9707.32354313</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant Renewal</gtr:description><gtr:end>2021-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A55F2C46-68DA-4A04-8C88-785332BD68D5</gtr:id><gtr:outcomeId>56d8168ca7f979.41038942</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New vaccines for global epidemics (Plague)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:id>275CAB4E-647F-474A-899F-7186260E01F1</gtr:id><gtr:outcomeId>58c41cb634dba2.23815956</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Proximity to discovery Industry Engagement Fund</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4787D8F6-85CA-46B7-B32C-0784D9AE7BAF</gtr:id><gtr:outcomeId>58b55cd3d668e1.58484486</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96252</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MND Association PhD Studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>31C73266-70DD-4713-9C09-D434076F9CB3</gtr:id><gtr:outcomeId>56dd3fac97de38.42435406</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46738</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK pilot grant</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>ARUK-PPG2017A-19</gtr:fundingRef><gtr:id>EDF4CB2E-2320-4749-BDD3-ADFAF01D66CC</gtr:id><gtr:outcomeId>58c82482a13259.86730267</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111924</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>641317</gtr:fundingRef><gtr:id>A6BD913B-3663-4990-942C-AF92A58A37E0</gtr:id><gtr:outcomeId>56d85b956aeae7.01357916</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>284176</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Stanley Medical Research Institute treatment trials</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Stanley Medical Research Institute (SMRI)</gtr:fundingOrg><gtr:id>92AA3395-B7E6-478B-B449-38E397A5550F</gtr:id><gtr:outcomeId>56d450c7a163c8.69160101</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4975434</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CRI: The Oxford Single Cell Biology Consortium (co-investigator)</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C8A23C95-E48B-4E16-96A1-79BCE0D47C65</gtr:id><gtr:outcomeId>5460c0b94ba886.11743611</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Discovery Award (co-investigator)</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7F5BD8C3-5CA7-4C1D-AD25-C131B5C9FDB9</gtr:id><gtr:outcomeId>56dff234548321.19662227</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Microstructural brain changes for diagnosis of cognitive disorders. This is an invention intended for application in medical imaging, particularly MRI.
The invention relates to methods of assessing or obtaining an indication of the presence of a cognitive disorder by analysing microstructural changes in regions of the brain. The invention particularly relates to methods of assessing or obtaining an indication of the presence of types of dementia, for example Alzheimer's disease, by analysing changes in minicolumns in regions or layers of the cortex of the brain or of the whole brain.</gtr:description><gtr:grantRef>MC_PC_13073</gtr:grantRef><gtr:id>A334FDD0-6740-45CB-913A-7EEA729D7B1A</gtr:id><gtr:impact>This IP will form a central part of a spin-out company that we expect to form in the next few months.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c82137c881c5.59360426</gtr:outcomeId><gtr:patentId>WO2016162682 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Microdetect</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Correlates unfolding with stability</gtr:description><gtr:id>03FF3347-8F4F-47D2-AE91-A45442463445</gtr:id><gtr:impact>Published and downloaded</gtr:impact><gtr:outcomeId>56dd92b8b7bfa6.89195555</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PULSAR</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>SWAS is an electrophysiological phenomenon that occurs under general anaesthesia. Our functional magnetic resonance imaging data suggest that at SWAS in an individual loses perception of incoming external stimuli. We developed Bayesian methods to characterise slow wave activity saturation (SWAS) in electroencephalography (EEG) data in off-line and real-time modes as there is significant translational potential for SWAS-based depth of anaesthesia monitoring.</gtr:description><gtr:id>44621F51-A353-475B-BB47-B20B86FB727F</gtr:id><gtr:impact>This is the first development step towards adaptive, smart and individualised depth of anaesthesia monitoring based on SWAS. This monitor will potentially help anaesthetists deliver the optimum anaesthetic dose and reduce the deleterious consequences of under- and over-anaesthesia. We have filed a patent based on perception loss at SWAS that includes this Bayesian modelling.</gtr:impact><gtr:outcomeId>56df84a1b491c0.25804843</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bayesian modelling of slow wave activity saturation</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This project has enabled the development and optimisation of a novel NMR screening protocol for the assessment of plasma protein binding, which simultaneously gives an assessment both of the level and location of binding. This information is particularly valuable for the design of new antibacterial agents with lowered plasma protein binding, a characteristic widely believed to enhance the level of bioactivity. Moreover, it has permitted initial work to demonstrate the viability of a wholly novel drug delivery system.</gtr:description><gtr:id>970BDF89-D8C3-4BED-B1B1-1E08C1045926</gtr:id><gtr:impact>Facilitated understanding a key aspect of antibacterial drug discovery</gtr:impact><gtr:outcomeId>56d471f25ad550.42077769</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NMR assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>. Our adenovirus-based vaccine technology is the first vaccine to our knowledge that uses human cells as the expression system for an outer membrane protein from extracellular bacteria, using the adjuvant properties of a viral vector. This is innovative as bacterial outer membrane proteins might not be expected to fold properly or to undergo the correct post-translational modifications in a mammalian cell, and our findings with a MenB antigen are innovative and promising.</gtr:description><gtr:id>0EF84E75-CCC5-4DF9-A6D2-0A3FCE765AEB</gtr:id><gtr:impact>Progress to GMP for phase I study</gtr:impact><gtr:outcomeId>56df59abe5c138.65909881</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>adenovirus-based vaccine technology</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Rapid calculation of ion mobility collision cross sections</gtr:description><gtr:id>8C6C1FA8-C15E-4641-A2BA-E21E6C4FDE4C</gtr:id><gtr:impact>Published and downloaded</gtr:impact><gtr:outcomeId>56dd9244db98a3.58709987</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IMPACT</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed an in vitro assay intending to measure antigen expression achieved in cell lines after infection by viral vectored vaccine candidate, in order to replace some of the mouse immunogenicity studies. The number of vaccine candidate developed with modifications, for example of the promoter, signal sequences or vector backbone, is high, and implies that a lot of mice are used to compare the immunogenicity of these vaccines. We believe that this approach could be refined, by measuring the level of antigen expressed by each vaccine in mice and human cells. We hypothesise that the level of antigen expression is a main driver of immunogenicity (albeit not the only one). Therefore screening of new vectors can be performed in cells rather than in animal experiment, in particular in the case of comparing vector backbones, as this is more likely to influence immunogenicity in a specie-specific manner. Therefore screening in cells, in particular human cells rather than mouse is highly relevant.</gtr:description><gtr:id>BE325570-8ABD-4B79-B1C0-F690491459CD</gtr:id><gtr:impact>In our group this technology has allowed understanding of mechanisms driving antigen expression fro viral vaccine candidates, as well as selection of vectors with optimal antigen expression for further testing in in vivo experiments.</gtr:impact><gtr:outcomeId>58bd7831908164.59340715</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Evaluation of in vitro antigen expression as a correlate of immunogenicity</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A novel method for differentiation of neuropsychiatric conditions based on the identification and modelling of signature patterns of microstructural change in the organisation of the cerebral cortex</gtr:description><gtr:id>12211B46-4E38-4138-B9CF-8D9450CD35ED</gtr:id><gtr:impact>This method forms part of a patent which has been filed.</gtr:impact><gtr:outcomeId>56d5a94743da20.99728520</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biosignatures in brain tissue</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>A novel software programme using the FSL platform was developed with collaborators in fMRIB for use in this analysis</gtr:description><gtr:id>3FCE9930-205E-4C52-BEE9-FD1CB701B3FB</gtr:id><gtr:impact>This software forms part of a patent that has been filed</gtr:impact><gtr:outcomeId>56d5a6e80a39e2.99018044</gtr:outcomeId><gtr:title>Cortical high intensity profile segmentation for MRI</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Oxford Antibiotics</gtr:companyName><gtr:description>Antibacterial drug discovery</gtr:description><gtr:id>37432815-BC7D-4E3C-B799-520E0E20D851</gtr:id><gtr:impact>None at this stage (too early), but in active discussion with industry and investors to map future directions</gtr:impact><gtr:outcomeId>56d46fc291f844.21287627</gtr:outcomeId><gtr:yearCompanyFormed>2017</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>6803BC99-84BD-42E0-9CB7-C33EC67B1051</gtr:id><gtr:title>Bullying victimisation and psychosis: The interdependence and independence of risk trajectories</gtr:title><gtr:parentPublicationTitle>BJPsych Advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b70a371258994cbc85c8abec358bfa73"><gtr:id>b70a371258994cbc85c8abec358bfa73</gtr:id><gtr:otherNames>Catone G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a69ea773ab855.65497980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C413774-6877-4F53-86DD-60EE6E190550</gtr:id><gtr:title>Quantifying the stabilizing effects of protein-ligand interactions in the gas phase.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e51686fe545b10732e914a906cdf08a"><gtr:id>6e51686fe545b10732e914a906cdf08a</gtr:id><gtr:otherNames>Allison TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d8570341ebb6.05904869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>940A4EEE-E58C-4CF0-AF09-68A696ACACD9</gtr:id><gtr:title>EMnIM: software for relating ion mobility mass spectrometry and electron microscopy data.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a9f4953285f3fd0af1e97a125c21b33"><gtr:id>5a9f4953285f3fd0af1e97a125c21b33</gtr:id><gtr:otherNames>Degiacomi MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>56d865f0715929.38899577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC6D7E53-5295-4EDC-91C3-120AD71F58B8</gtr:id><gtr:title>Studying epigenomics in single cells: what is feasible and what can we learn?</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6951a04aa0c935290484392c1117ca4"><gtr:id>e6951a04aa0c935290484392c1117ca4</gtr:id><gtr:otherNames>Wills QF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>56ab581c195825.74271542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259C1536-0F13-4984-A98E-A1C654579B6E</gtr:id><gtr:title>Structural and Biochemical Characterization of Rm3, a Subclass B3 Metallo-?-Lactamase Identified from a Functional Metagenomic Study.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efa19b74bcd8e6ddb3c47b9529ff96ee"><gtr:id>efa19b74bcd8e6ddb3c47b9529ff96ee</gtr:id><gtr:otherNames>Salimraj R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5899e9f3670582.88037651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>191023F5-E0F7-4351-BFAE-B90C6E1CC447</gtr:id><gtr:title>NMR-filtered virtual screening leads to non-metal chelating metallo-?-lactamase inhibitors.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07111f4196fe043435d46d8db76cbef8"><gtr:id>07111f4196fe043435d46d8db76cbef8</gtr:id><gtr:otherNames>Li GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>58999febb710b1.28288856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7149D931-D8FC-4962-BFC5-6AEB977EB488</gtr:id><gtr:title>Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c07a2cd5141499e3dde9061d97e21333"><gtr:id>c07a2cd5141499e3dde9061d97e21333</gtr:id><gtr:otherNames>Zandi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>56d45510c717d0.82542720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>012AFAAA-F61E-421E-B0D4-9B44F9EC9B17</gtr:id><gtr:title>The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87ef9c2b6ecc67c7a071d86efe5f9ae2"><gtr:id>87ef9c2b6ecc67c7a071d86efe5f9ae2</gtr:id><gtr:otherNames>Rollier CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>5a7ae80f87dc64.97360147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>869A774A-67A6-4CE3-80BB-460813B597B5</gtr:id><gtr:title>Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2107490ba1ae5f5dd21b0c1d4add91ca"><gtr:id>2107490ba1ae5f5dd21b0c1d4add91ca</gtr:id><gtr:otherNames>Calvopi?a K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>577d0e4bbcdb31.34600177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E925416-0352-4492-8158-236D670903CD</gtr:id><gtr:title>Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity.</gtr:title><gtr:parentPublicationTitle>Antibiotics (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2079-6382</gtr:issn><gtr:outcomeId>58c66d52cf1176.75611543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D3FA189-C481-4C6A-969A-F6FC20F5140A</gtr:id><gtr:title>Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a34564130b5491ddf263c1bfe04b73d4"><gtr:id>a34564130b5491ddf263c1bfe04b73d4</gtr:id><gtr:otherNames>Foerster J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>56d99397061005.51271415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CF0E447-FCD2-43DD-82F3-C7206CDCBF49</gtr:id><gtr:title>Treating Sleep Problems in Young People at Ultra-High Risk of Psychosis: A Feasibility Case Series.</gtr:title><gtr:parentPublicationTitle>Behavioural and cognitive psychotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5592abb0acfc0604d67da2a0c7fb585"><gtr:id>e5592abb0acfc0604d67da2a0c7fb585</gtr:id><gtr:otherNames>Bradley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1352-4658</gtr:issn><gtr:outcomeId>5a69ea77c5a6c6.72906096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>233DF561-347C-4E8D-B326-73534EC78581</gtr:id><gtr:title>Viral vectors as vaccine platforms: from immunogenicity to impact.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2787dfca57d8c2fdc2e07cd71617963"><gtr:id>a2787dfca57d8c2fdc2e07cd71617963</gtr:id><gtr:otherNames>Ewer KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>5a7ae799612e32.89066982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F34B1168-7339-422C-AD1E-4D8EBB57EFDD</gtr:id><gtr:title>Scalar Cross-Relaxation Detected in the NOESY Spectra of Oxazolidines and Thiazolidines.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bce4f4599669dd632b39e1d3770594c2"><gtr:id>bce4f4599669dd632b39e1d3770594c2</gtr:id><gtr:otherNames>Panduwawala TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>58c66d151a9bb0.08167709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A0FB46-0F0E-4574-91A7-B65726D34B69</gtr:id><gtr:title>Investigations on recyclisation and hydrolysis in avibactam mediated serine ?-lactamase inhibition.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09e36c120da7c68a327600769ab29add"><gtr:id>09e36c120da7c68a327600769ab29add</gtr:id><gtr:otherNames>Choi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>589ae04fd3b408.61986621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2619E3EC-BE68-47DB-AECD-2F42A35D15AD</gtr:id><gtr:title>Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9d06d07b22b4e47a32b6812ae82e4f7"><gtr:id>e9d06d07b22b4e47a32b6812ae82e4f7</gtr:id><gtr:otherNames>Al-Diwani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5a69ea779954d2.89274498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2F50914-39EA-415F-A470-ADA8B7B7B6DA</gtr:id><gtr:title>Application of single-cell genomics in cancer: promise and challenges.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6951a04aa0c935290484392c1117ca4"><gtr:id>e6951a04aa0c935290484392c1117ca4</gtr:id><gtr:otherNames>Wills QF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56ab5834284d91.66364025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F43CAC16-342E-44F5-B300-2D24C4DFD13E</gtr:id><gtr:title>C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9518a7f05163862ae602b67902c07daf"><gtr:id>9518a7f05163862ae602b67902c07daf</gtr:id><gtr:otherNames>Aoki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58c13c0520e422.01529440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BFBA806-04EE-4475-AE5D-78432839913D</gtr:id><gtr:title>Investigation of Slow-wave Activity Saturation during Surgical Anesthesia Reveals a Signature of Neural Inertia in Humans.</gtr:title><gtr:parentPublicationTitle>Anesthesiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b220c8db1ea391ce8b856948edcc9141"><gtr:id>b220c8db1ea391ce8b856948edcc9141</gtr:id><gtr:otherNames>Warnaby CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-3022</gtr:issn><gtr:outcomeId>5aa925998b75b1.46497571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AA25BBF-DDBA-442C-A0C4-762D8F0AF7E8</gtr:id><gtr:title>Interaction of Avibactam with Class B Metallo-?-Lactamases.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de25d97265faf8f908a2a6c9c11892a"><gtr:id>6de25d97265faf8f908a2a6c9c11892a</gtr:id><gtr:otherNames>Abboud MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>581b5652530862.71165362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E48709DB-D1E7-46C6-A164-98ABF8E4D4F3</gtr:id><gtr:title>Collision cross sections for structural proteomics.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16ebee0593a5c2f91904c0ecd1c4affb"><gtr:id>16ebee0593a5c2f91904c0ecd1c4affb</gtr:id><gtr:otherNames>Marklund EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>56d86583ea3162.25806816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>628D94D9-2B59-46B5-AE17-89A7375EF7BD</gtr:id><gtr:title>Maximising value from a United Kingdom Biomedical Research Centre: study protocol.</gtr:title><gtr:parentPublicationTitle>Health research policy and systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beed982914227a0221c1916225095a78"><gtr:id>beed982914227a0221c1916225095a78</gtr:id><gtr:otherNames>Greenhalgh T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-4505</gtr:issn><gtr:outcomeId>5a6f2ddc10a598.72136548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C611F2A-CFC5-4072-A94A-265361B5ACDD</gtr:id><gtr:title>The road to avibactam: the first clinically useful non-?-lactam working somewhat like a ?-lactam.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3208f709bc1abed42116c259aef6b15"><gtr:id>e3208f709bc1abed42116c259aef6b15</gtr:id><gtr:otherNames>Wang DY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>5899e9f3366b75.00842244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4E796B-A9F5-4F4D-81FF-D3476C7D9BF0</gtr:id><gtr:title>Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab8e8f7d43db2d02f8fbaf90a095239"><gtr:id>4ab8e8f7d43db2d02f8fbaf90a095239</gtr:id><gtr:otherNames>Giustacchini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5a34f5d58119f4.89159883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E43B6CD8-0DC2-4D6B-A5B4-BFCA3AA95448</gtr:id><gtr:title>Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ef346aeead2484cf626622ed68af884"><gtr:id>5ef346aeead2484cf626622ed68af884</gtr:id><gtr:otherNames>Marty MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>doi_55f98598574ac644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4F2AEA-0042-4B9C-929E-DC1FDA95766A</gtr:id><gtr:title>Article</gtr:title><gtr:parentPublicationTitle>Neural Inertia and Slow Wave Activity Saturation identified during Surgical Anesthesia in Humans</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fc3e4d22d1df69e5e400923f2855c51"><gtr:id>7fc3e4d22d1df69e5e400923f2855c51</gtr:id><gtr:otherNames>Warnaby CE*</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56de25b9a38c77.46515152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>829F1D4B-BA5D-4DD9-A0C2-34705300BF35</gtr:id><gtr:title>Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d34843118266b9b58acb86987295e453"><gtr:id>d34843118266b9b58acb86987295e453</gtr:id><gtr:otherNames>Urbanucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a6f2ed2eeffc8.34842459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0949279-4E46-44E0-9D72-28135E1E89F7</gtr:id><gtr:title>Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a153ccf6d3e6dd4a10a5fe993d848d64"><gtr:id>a153ccf6d3e6dd4a10a5fe993d848d64</gtr:id><gtr:otherNames>Psaila B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>58b5449d949b76.96389303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10E460EF-6C90-42C0-952E-78236857E13C</gtr:id><gtr:title>Insights into the Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures of the Catalytic Domain of MCR-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/befc58d95b309466ced570b65ae0e450"><gtr:id>befc58d95b309466ced570b65ae0e450</gtr:id><gtr:otherNames>Hinchliffe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>587f4525bef883.91282592</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13073</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>